The short answer
High-dose nicotinic acid can worsen glucose control while you take glimepiride. Arrange monitoring with your prescriber if it is being considered. This is not evidence that glimepiride creates a need for niacin, and spacing doses has not been established as a solution.
What this answer covers
Pharmacologic oral nicotinic acid with glimepiride; ordinary dietary niacin, nicotinamide and other vitamin B3 products are not automatically equivalent.
- Supplement or preparation
- Niacin
- Medication ingredient
- glimepiride
The medication label names nicotinic acid
Nicotinic acid is listed among agents that can reduce glimepiride’s glucose-lowering effect. The label advises observing glucose control when these agents are started or withdrawn. The issue is possible loss of control, not a proven niacin deficiency caused by glimepiride.
Form and amount change the concern
The nutrient guidance identifies high-dose nicotinic acid as a concern for raised glucose. This should not be generalized to every food containing vitamin B3 or to a different form such as nicotinamide. Check the actual formulation and daily amount.
A large trial supports caution about high-dose therapy
A large vascular-disease trial reported more serious diabetes-control problems with extended-release niacin plus laropiprant. It was a combination treatment and did not provide a glimepiride-specific estimate. Its results are not a reason to restrict ordinary dietary niacin.
Monitoring is more relevant than spacing
Separating doses has not been shown to prevent this metabolic effect. If nicotinic acid is prescribed, coordinate its purpose, dose and glucose follow-up with the clinician. Do not independently increase glimepiride to compensate for a supplement.
Evidence and practical considerations
Timing & monitoring
High-dose nicotinic acid can worsen glucose control while you take glimepiride. Arrange monitoring with your prescriber if it is being considered. This is not evidence that glimepiride creates a need for niacin, and spacing doses has not been established as a solution.
- Exact scope
- Pharmacologic oral nicotinic acid with glimepiride; ordinary dietary niacin, nicotinamide and other vitamin B3 products are not automatically equivalent. with Oral glimepiride tablets for type 2 diabetes.
- Medication form and route
- oral
What remains uncertain
- No quantified exact-pair risk or protective spacing interval is established. Original-source access and population limitations are documented individually.
Factors that may matter: Exact preparation and amount; Other glucose-lowering treatment; Meal schedule, kidney function and glucose readings.
Read the supporting source summaries
Source 1: Current U.S. regulatory product labeling
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: Adults with type 2 diabetes using oral glimepiride.
Glimepiride can cause severe hypoglycemia. Nicotinic acid is listed among agents that may reduce glucose control. The specified four-hour-before instruction applies to colesevelam.
How this applies: Exact medication labeling provides administration and monitoring context, not proof of untested supplement effects.
The label does not establish every botanical interaction. Colesevelam instructions cannot be transferred to charcoal, glucomannan or other supplements.
Source 2: Federal nutrient guidance
ods.od.nih.gov · Source check Sep 10, 2026
Population: People taking antidiabetes medicines and high-dose nicotinic acid.
Large nicotinic-acid doses can raise glucose; monitoring is advised during co-use with antidiabetes medicines.
How this applies: Supports the form- and dose-specific concern in the exact medication label.
General guidance does not quantify glimepiride-specific risk or establish a timing workaround.
Source 3: Original human study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: 25,673 patients with vascular disease.
Active treatment increased serious disturbances in diabetes control.
How this applies: Clinical context for high-dose therapy, not evidence that normal dietary niacin requires restriction.
Combination treatment; does not isolate niacin from laropiprant or establish a glimepiride-specific rate.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Article prepared | |
| Initial source-checked research draft. Exact preparations, contrary findings and study limitations documented; clinical review not recorded. | |
| Research summary published |
Article revision: 8dc45a49d2596e7d
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.